key: cord-0992497-acyt9tw6
authors: Murillo-Berlioz, Alejandro; Guinn, Nicole R.; Levy, Jerrold H.; Milano, Carmelo A.
title: Arterial and Venous Thrombosis complicating Coronary Artery Bypass Grafting after use of Epoetin Alfa-epbx
date: 2020-08-04
journal: JTCVS Tech
DOI: 10.1016/j.xjtc.2020.07.018
sha: 9ee1e34b2f350bd776b5d3a14a2a2f31a80a5ea1
doc_id: 992497
cord_uid: acyt9tw6

nan

We would like to add to the evidence that the use of erythropoietin stimulating agents for 25 preoperative anemia in patients undergoing cardiac surgery may carry a substantial risk of 26 thrombotic events. anemia may outweigh potential thrombotic risks. A proposed mechanism for increased 78 thrombotic events is an increase in platelet activation and thrombocytosis. 4 We report a patient 79 treated with epoetin alfa-epbx before coronary artery bypass grafting (CABG) who was at a low 80 risk for perioperative thrombotic events but experienced both pulmonary and major arterial 81 thrombotic complications postoperatively. Written informed consent was obtained. 82

A 73-year-old African American female was evaluated for an elective coronary artery bypass 85 grafting (CABG) due to symptomatic, severe left main coronary artery disease. Her medical 86 history included well-controlled hypertension, type 2 diabetes mellitus, transient ischemic 87 attacks, and ischemia with a prior percutaneous coronary intervention (PCI) and drug-eluting 88 stent (DES) placed to the left anterior descending (LAD) artery. She was a Jehovah's Witness 89 and was evaluated by our blood conservation program, which recommended preoperative 90 intravenous iron supplementation, folate, vitamin B12, minimizing blood draws, and Epoetin-91 alfa 300units/kg daily for 10 days to augment preoperative hemoglobin concentration. 5 92 normal laboratory values. A heparin infusion was started for unstable angina, and after receiving 94 8 epoetin alfa-epbx and 5 ferric gluconate doses, she had on-going chest pain and required urgent 95 surgery. Hemoglobin and platelet count prior to surgery was 12.5g/dL and 207,000, respectively. To our knowledge, this is the first reported case of simultaneous arterial and venous thrombosis 122 in a patient who received preoperative ESAs prior to heart surgery, despite being determined to 123 be low risk for thrombosis. Intraoperative transesophageal echocardiography testing with color 124 doppler and bubble study was negative for a patent foramen ovale. She received pre and 125 postoperative aspirin. Her thrombotic events occurred less than 7 days after her index procedure 126 and she tested negative for COVID-19, a potential cause. Further workup for prothrombotic 127 conditions was also negative. Nonetheless, ESAs remain an important component of anemia 128 treatment, particularly for those patients for whom transfusion is not an option, and the lowest 129 effective dose should be utilized. As the use of epoetin-alfa becomes more common for patients 130 with preoperative anemia, its benefits must be weighed against possible increased risk of major 131 thrombotic events, and consideration should be given for the potential need for postoperative 132 pharmacologic thrombosis prophylaxis. 

Update to The Society of Thoracic Surgeons and 161 the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice 162

Guidelines * The Society of Thoracic Surgeons Blood Conservation Guideline Task 163

Force : The Society of Cardiovascular Anesthesiologists Special Task Force on Blood 164

Transfusion : The International Consortium for Evidence Based Perfusion : ATS

Blood Management for Adult Cardiac Surgery The Task Force on Patient Blood 168

Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic 169

Surgery ( EACTS ) and the European Association of Cardiothoracic Anaesthesiology ( 170 EACTA ) Odds Ratio Platelet Concentrate

The influence of Erythropoietin on platelet 173 activation , thrombin generation and FVII / active FVII in patients with AMI